Superdisintegrants Market to reach US$ 659.17 million by 2027 Says, The Insight Partners

According to The Insight Partners market research study of ‘‘Superdisintegrants Market to 2027 – Global Analysis and Forecasts by Type, Formulation, Therapeutic Area, Application’ the global Superdisintegrants market is projected to reach US$ 659.17 Mn in 2027 from US$ 369.56 Mn in 2019. The market is projected to grow with a CAGR of 7.6% from 2020-2027. The report provides trends predominating in the global superdisintegrants market and the factors driving the market and also the factors that act as hindrances.

The superdisintegrants are the agents that are mixed in the tablets to intensify the breakup of the tablet into small fragments in aqueous conditions, thereby boosting the release of the drug into the body. In past years superdisintegrants have gained the attention of the pharmaceutical industry as it increases the solubility of active pharmaceutical ingredient (API) in the body by raising the absorption of the drug in the body due to which bioavailability of drugs also increases. The superdisintegrant agent is used in tablets and capsules.

The global superdisintegrants market is driven by growing adoption of orally disintegrating drugs and increasing acceptability of generic drugs but, the high cost associated with manufacturing of superdisintegrants is expected to restrain the market growth during the forecast period. However, emerging countries such as India, Brazil are likely to deliver high growth opportunity to improve market share for industry player in near future.

Get sample Research on Superdisintegrants Market study at:

Superdisintegrants Market Competitive Landscape

The Superdisintegrants market majorly consists of players such as Ashland Inc., Basf SE, DowDupont, JRS Pharma, DFE Pharma, Roquette, Asahi Kasei Corporation, Merck KGAA, Corel Pharma Chem, Avantor Performance Materials, LLC., and others. Several companies are concentrating on organic strategies, such as product launch and product approvals. For instance, in April 2018, the partnership of Perrigo Company Plc and Dexcel Pharma Technologies Ltd. launched Omeprazole ODT—orally disintegrating tablets to treat heartburn. The company took strategic step to expand geriatric customer base.

Growing Adoption of Orally Disintegrating Drugs

The world is witnessing exponential growth in the prevalence of chronic diseases. Factors such as progression of viruses, bacteria, parasites, coupled with growing adoption of sedentary lifestyle, genetic conditions, and consumption of poor diet are responsible for the growing prevalence of these diseases. This exponential increase in the prevalence of diseases is leading to the adoption of solid dosage forms for disease treatment. For instance, according to data published by the World Health Organization (WHO) in 2019, an estimated 71.0 million people suffer from hepatitis C virus infection across the world. Oral drug delivery remains the most common route of drug administration in the healthcare world. Solid dosage forms typically include tablets, capsules, and powders for the treatment of particular disease condition. Moreover, growing emphasis on novel drug delivery approach is expected to boost the awareness and focus on the utilization of orally disintegrating tablets during the forecast period. Superdisintegrants or orally disintegrating tablets are gaining traction due to advantages such as ease of drug administration and better compliance for pediatric and geriatric patients.

Furthermore, superdisintegrant tablets offer several benefits over traditional capsules and tablets. Advantages of disintegrants include the ability for accurate dosing, fast action, superior patient compliance, better palatability, and cost effectiveness, as well as ease of administration, no risk of airway suffocation during swallowing, and flexibility in terms of large and small molecules. Such salient features of superdisintegrant tablets represent massive potential for its adoption during tablet formulations. Moreover, on-going research and development activities conducted by major players and research institutes are likely to expand the range of benefits offered by superdisintegrants during the forecast period. Additionally, the increasing adoption of orally disintegrating tablets is attributable to new product launches by several pharmaceutical companies. For instance, in April 2018, the partnership of Perrigo Company Plc. and Dexcel Pharma Technologies Ltd. launched Omeprazole ODT—orally disintegrating tablets to treat heartburn. The company took strategic step to expand geriatric customer base.

Superdisintegrants Market Segmentation Review

The superdisintegrants market based on type is segmented into synthetic superdisintegrants, natural superdisintegrants, and other superdisintegrants. In 2019, the synthetic superdisintegrants segment accounted for the largest market share in the global superdisintegrants market. The growth of the synthetic superdisintegrants segment is expected to grow due to the wide consumption of these superdisintegrants in numerous pharmaceutical drug formulations owing to the benefits offered such as efficiency at lesser concentrations as compared to starch and a smaller effect on the compressibility and flow ability of the dosage form. These factors are increasing the demand of synthetic superdisintegrants in the forecast period.

The superdisintegrants market, based on formulation, has been segmented into tablets and capsules. The tablets segment held the largest share of the global superdisintegrants market, attributing to the fact that tablets are widely prescribed solid dosage form for any disease condition, the adoption of tablets is considerably high as it offers better dosage administration and uniformity, which further propel the growth of the alumina segment in the global superdisintegrants market. Moreover, the segment is expected to register the fastest growth rate in the market during the forecast period.

Buy Complete Report of Superdisintegrants Market at:

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:


Phone: +1-646-491-9876


Back to news